Omacetaxine Homoharringtonine CAS: 26833-87-4

CAS NO: 26833-87-4
Omacetaxine Homoharringtonine
Chemical Name: Homoharringtonine
Molecular Formula: C29H39NO9
Formula Weight: 545.63
CAS No.: 26833-87-4
Description Review
Description

Omacetaxine, also known as Homoharringtonine, is a type of chemotherapy medication used to treat chronic myeloid leukemia. It belongs to the class of drugs called protein synthesis inhibitors that prevent cancer cells from growing and dividing. Omacetaxine Homoharringtonine CAS: 26833-87-4 is the chemical compound that has been widely studied for its effectiveness in treating this type of leukemia.

Chemical Name:

The chemical name for Omacetaxine Homoharringtonine is (1S,3R,4R,5R,8R,9S,10R,11S,12R,13R)-3-((2S,3R,4S,6R)-4-amino-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)-7,8,9,10-tetrahydro-6,11-dihydroxy-9,13-dimethyl-5-(1-methylpropyl)oxacyclododeca[3,2-d]pyridin-2,4,6,12(1H,3H,5H,7H,8H,9H,11H)-heptone.

Molecular Formula:

The molecular formula of Omacetaxine Homoharringtonine is C29H39N5O8.

Formula Weight:

The formula weight of Omacetaxine Homoharringtonine is 569.65 g/mol.

CAS No:

The CAS number for Omacetaxine Homoharringtonine is 26833-87-4.

Top Ten Keywords and Synonyms:

  1. Omacetaxine mepesuccinate
  2. Homoharringtonine
  3. Chronic myeloid leukemia
  4. Protein synthesis inhibitors
  5. Hematologic malignancies
  6. Cancer chemotherapy
  7. Tyrosine kinase inhibitors
  8. Synthetic analogs
  9. FDA approved drug
  10. Anti-cancer agents

Other synonyms for Omacetaxine Homoharringtonine include Ceflatonin, Homoharringtonine Sulfate, NSC-107010, and HHT.

Health Benefits:

Omacetaxine Homoharringtonine has been shown to be effective in the treatment of chronic myeloid leukemia, a type of cancer that affects the blood and bone marrow. It works by slowing down or stopping the growth and division of cancer cells. Studies have shown that Omacetaxine Homoharringtonine can help patients with chronic myeloid leukemia who have become resistant to other treatments.

Potential Effects:

The potential effects of Omacetaxine Homoharringtonine include decreased production of white blood cells, red blood cells, and platelets. This can lead to an increased risk of infections, bleeding, and anemia. Other potential effects include fatigue, nausea, vomiting, diarrhea, fever, muscle pain, and dizziness.

Product Mechanism:

Omacetaxine Homoharringtonine works by inhibiting protein synthesis in cancer cells. Specifically, it binds to the ribosome, which is responsible for assembling proteins, and prevents it from working properly. This slows down or stops the growth and division of cancer cells.

Safety:

Omacetaxine Homoharringtonine should only be used under the supervision of a qualified healthcare provider. It can cause serious side effects, including decreased production of blood cells, liver damage, and kidney damage. Patients who are allergic to Omacetaxine Homoharringtonine or any of its ingredients should not use this medication. It is important to tell your healthcare provider about all medications you are taking before starting treatment with Omacetaxine Homoharringtonine.

Side Effects:

Common side effects of Omacetaxine Homoharringtonine include fatigue, nausea, vomiting, diarrhea, fever, muscle pain, and dizziness. Less common side effects include respiratory infections, anemia, and decreased appetite. Serious side effects may include decreased production of blood cells, liver damage, and kidney damage.

Dosing Information:

The dose of Omacetaxine Homoharringtonine will depend on the patient's age, weight, and overall health. The medication is usually given as an injection into the muscle or vein. Treatment may continue for several weeks or months.

Conclusion:

Omacetaxine Homoharringtonine is a chemotherapy medication used to treat chronic myeloid leukemia. It works by inhibiting protein synthesis in cancer cells, slowing down or stopping their growth and division. While it can be effective in treating this type of leukemia, it can also cause serious side effects and should only be used under the supervision of a qualified healthcare provider

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code